Are Site Networks the Solution to the Industry Productivity and Recruitment Challenge?
Update: 2025-06-25
Description
Summary:
The consolidation of independent clinical trial sites into larger, integrated networks represents a strategic evolution in clinical research. This panel from the 2024 DPHARM conference discusses whether or not this level of consolidation can bring new researchers and new sites into clinical research, and lead to reduced risk to sponsors, increased predictability, streamlined site operations and greater access for patients.
More specifically, this panel focuses on:
For more information, go to DPHARMconference.com.
The consolidation of independent clinical trial sites into larger, integrated networks represents a strategic evolution in clinical research. This panel from the 2024 DPHARM conference discusses whether or not this level of consolidation can bring new researchers and new sites into clinical research, and lead to reduced risk to sponsors, increased predictability, streamlined site operations and greater access for patients.
More specifically, this panel focuses on:
- What is the true value of site networks?
- What does the landscape look like today – by TA/country / region?
- If scaled, what will the benefit look like for patients and can it impact the speed of treatment to patients?
- Case examples of the impact of current clinical research networks
- Mark Travers, PhD, MBA, VP, Head of GCTO Regions, Monitoring Excellence, Global Operations and eTMF, Merck
- Paul Evans, President and CEO, Velocity Clinical Research
- Mark Scullion, MBA, CEO, Atlas Clinical Research
- Nick Slack, MBE, Chairman and CEO, The START Center for Cancer Research
For more information, go to DPHARMconference.com.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
